A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients

Journal of Infection

Volumn 35, Issue 3, 1997, Pages 225-230

  Soriano, V ^a,h   Bravo, R ^a   Garcia Samaniego J ^a   Ortega, E ^b   Gonzalez J ^c   Colmenero, M ^d   Castilla, J ^e   Castro, A ^f   Suarez D ^g   Pedreira, J ^f   Lopez Calvo S ^f   Llibre, J Ma ⁱ   Martinez Odriozola P ^j   Santamaria J M ^j   Gonzalez Anglada, I ^c   Martinez Zapico R ^c   Vazquez J J ^c   Rodriguez Pinero F J ^d   Carballo, E ^k   Matinez Vazquez J M ^k   Herrera, A ^b   Del Romero, J ^l   Rodriguez C ^l   Garcia S ^l   Moreno, A ^m   Cosin J ⁿ   Zabay, J Ma ⁿ   Mas, A ^a   Gomez Cano Ma ^a   Gonzalez Lahoz J ^a   more..

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^e CARLOS III INSTITUTE OF HEALTH   (Spain)

^f HOSPITAL JUAN CANALEJO   (Spain)

^g Universidad de La Coruña   (Spain)

^h Hospital Juan Canalejo ^*  (Spain)

ⁱ Hospital de Calella   (Spain)

^j HOSPITAL DE BASURTO   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^l CENTRO SANITARIO SANDOVAL   (Spain)

^m HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CD4 ANTIGEN; INTRON R; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD TRANSFUSION; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INTRAVENOUS DRUG ABUSE; LIFE EXPECTANCY; LIVER CIRRHOSIS; LIVER FAILURE; LYMPHOCYTE COUNT; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; RELAPSE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 13144258783     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(97)92776-6     Document Type: Article

References (32)

1. Martin P, Di Bisceglie A, Kassianides C, Lisker-Melman M, Hoofnagle J. Rapidly progressive non-A, non-B hepatitis in patients with HIV infection. Gastroenterology 1989; 97: 1559-1561.
2. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of haemophilia patients. Br J Haematol 1994; 87: 555-561.
3. Eyster M, Diamondstone L, Lien J, Ehmann W, Quan S, Goedert J. The natural history of hepatitis C virus (HCV) infection in multitransfused hemophiliacs: effect of coinfection with HIV. J AIDS 1993; 6: 602-610.
4. Sánchez-Quijano A, Andreu J, Gavilán F et al. Influence of HIB type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-953.
5. Sabin C, Phillips A, Elford J, Griffiths P, Janossy G, Lee C. The progression of HIV disease in a haemophiliac cohort followed for 12 years. Br J Haematol 1993; 83: 330-333.
6. Lee C, Sabin C, Phillips A, Elford J, Pasi J. Morbidity and mortality from transfusion-transmtted disease in haemophilia. Lancet 1995; 345: 1309.
7. Soriano V, García-Samaniego J, Bravo R, Gutiérrez M, González-Lahoz J. High morbidity and mortality with chronic viral liver disease in HIV-infected individuals in Spain. J Infect 1994; 28: 100-101.
8. Jover R, Gutiérrez A, Boix V, Portilla J. Mortality caused by chronic liver disease in HIV-infected patients. Med Clin (Barc) 1995; 105: 48.
9. Fried M, Hoofnagle J. Therapy of Hepatitis C. Sem Liver Dis 1995; 15: 82-91.
10. Marcellin P, Boyer N, Giostra E et al. Recombinant human IFN in patients with chronic non A-non B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
11. Boyer N, Marcellin P, Degott C, Degos F, Saimot A, Erlinger S. Recombinant interferon alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992; 165: 723-726.
12. Marriott E, Navas S, Del Romero J et al. Treatment with recombinant interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993; 40: 107-111.
13. Soriano V, García-Samaniego J, Bravo R et al. Efficacy and safety of interferon treatment for chronic hepatitis C in HIV-infected patients. J Infect 1995; 31: 9-13.
14. Knodell R, Ishak K, Black W. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
15. Stuyver L, Rossau R, Wyseur A et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-1102.
16. Lau J, Davis G, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504.
17. Camps J, Crisóstomo S, García-Granero M, Riezu-Boj J, Civeira P, Prieto J. Prediction of the response of chronic hepatitis C to interferon alpha: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714-1717.
18. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1993; 329: 143.
19. Hagiwara H, Hayashi N, Mita E et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993; 104: 877-883.
20. Tsubota A, Chayama K, Ikeda Y et al. Factors predictive of response to interferon therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-1094.
21. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-17.
22. Davis P. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994; 21: 1-3.
23. Aiyama T, Yoshioka K, Takayanagi M, Iwata K, Okumura A, Kakumu S. Serum HCV RNA titer at the end of interferon therapy predicts the long-term outcome of treatment. J Hepatol 1995; 23: 497-502.
24. Marcellin P, Puteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alpha in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-165.
25. Bosch O, Tapia L, Quiroga J, Carreño V. An escalating dosage of recombinant interferon alpha-2a in the treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-149.
26. Chemello L, Bonetti P, Cavalletto L et al. Randomized trial comparing three different regimens of alpha-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-706.
27. Di Bisceglie A, Martin P, Kassianides C et al. Recombinant alpha-interferon therapy for chronic hepatitis C. A randomized double blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
28. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
29. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Bassetti D. Rapid decline of CD4 + cells after IFNa treatment in HIV-1 infection. Lancet 1993; 341: 958-959.
30. Pesce A, Taillan B, Rosenthal E. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1597.
31. Soriano V, Bravo R, García-Samaniego J et al. CD4+ T-lympho-cytopenia in HIV-infected patients ongoing interferon therapy for chronic hepatitis C. AIDS 1994; 8: 1621-1622.
32. Schvarcz R, Yun Z, Sonneborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46: 43-47.